Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FiLeClo is a Polish biotechnology company focused on developing a multi-target small-molecule drug platform based on semisynthetic derivatives of salinomycin, a natural polyether ionophore. The company's proprietary platform aims to revolutionize cancer treatment by selectively targeting cancer stem cells and metastasis while overcoming drug resistance and avoiding the severe toxic side effects associated with traditional chemotherapy. FiLeClo's lead candidate, FLC-436, is a highly active and selective cytostatic drug candidate entering Phase 1 clinical trials for solid tumors. Beyond oncology, the company is leveraging its ionophore chemistry expertise to develop preclinical programs for obesity (FLC-XAO, a mitochondrial uncoupler), Gram-positive bacterial infections (FLC-XAB), viral infections (FLC-XAV), and protozoal infections (FLC-XAP).
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fileclo.